Literature DB >> 31589252

Global Prevalence of Hypertension in Children: A Systematic Review and Meta-analysis.

Peige Song1, Yan Zhang2, Jinyue Yu3, Mingming Zha4, Yajie Zhu5, Kazem Rahimi5, Igor Rudan1.   

Abstract

Importance: Reliable estimates of the prevalence of childhood hypertension serve as the basis for adequate prevention and treatment. However, the prevalence of childhood hypertension has rarely been synthesized at the global level. Objective: To conduct a systematic review and meta-analysis to assess the prevalence of hypertension in the general pediatric population. Data Sources: PubMed, MEDLINE, Embase, Global Health, and Global Health Library were searched from inception until June 2018, using search terms related to hypertension (hypertension OR high blood pressure OR elevated blood pressure), children (children OR adolescents), and prevalence (prevalence OR epidemiology). Study Selection: Studies that were conducted in the general pediatric population and quantified the prevalence of childhood hypertension were eligible. Included studies had blood pressure measurements from at least 3 separate occasions. Data Extraction and Synthesis: Two authors independently extracted data. Random-effects meta-analysis was used to derive the pooled prevalence. Variations in the prevalence estimates in different subgroups, including age group, sex, setting, device, investigation period, BMI group, World Health Organization region and World Bank region, were examined by subgroup meta-analysis. Meta-regression was used to establish the age-specific prevalence of childhood hypertension and to assess its secular trend. Main Outcomes and Measures: Prevalence of childhood hypertension overall and by subgroup.
Results: A total of 47 articles were included in the meta-analysis. The pooled prevalence was 4.00% (95% CI, 3.29%-4.78%) for hypertension, 9.67% (95% CI, 7.26%-12.38%) for prehypertension, 4.00% (95% CI, 2.10%-6.48%) for stage 1 hypertension, and 0.95% (95% CI, 0.48%-1.57%) for stage 2 hypertension in children 19 years and younger. In subgroup meta-analyses, the prevalence of childhood hypertension was higher when measured by aneroid sphygmomanometer (7.23% vs 4.59% by mercury sphygmomanometer vs 2.94% by oscillometric sphygmomanometer) and among overweight and obese children (15.27% and 4.99% vs 1.90% among normal-weight children). A trend of increasing prevalence of childhood hypertension was observed during the past 2 decades, with a relative increasing rate of 75% to 79% from 2000 to 2015. In 2015, the prevalence of hypertension ranged from 4.32% (95% CI, 2.79%-6.63%) among children aged 6 years to 3.28% (95% CI, 2.25%-4.77%) among those aged 19 years and peaked at 7.89% (95% CI, 5.75%-10.75%) among those aged 14 years. Conclusions and Relevance: This study provides a global estimation of childhood hypertension prevalence based on blood pressure measurements in at least 3 separate visits. More high-quality epidemiologic investigations on childhood hypertension are still needed.

Entities:  

Mesh:

Year:  2019        PMID: 31589252      PMCID: PMC6784751          DOI: 10.1001/jamapediatrics.2019.3310

Source DB:  PubMed          Journal:  JAMA Pediatr        ISSN: 2168-6203            Impact factor:   16.193


  69 in total

Review 1.  ACE2 (Angiotensin-Converting Enzyme 2), COVID-19, and ACE Inhibitor and Ang II (Angiotensin II) Receptor Blocker Use During the Pandemic: The Pediatric Perspective.

Authors:  Andrew M South; Tammy M Brady; Joseph T Flynn
Journal:  Hypertension       Date:  2020-05-05       Impact factor: 10.190

2.  Late referrals of pediatric patients with elevated blood pressure.

Authors:  Guido Filler; Laura Torres-Canchala
Journal:  Pediatr Nephrol       Date:  2020-02-11       Impact factor: 3.714

3.  Monitoring of Excess Body Weight in Children in the Emergency Department of a Tertiary Pediatric Hospital in Bucharest, Romania.

Authors:  Victor Daniel Miron; Gabriela Bar; Claudiu Filimon; Vlad Alexandru Gaidamut; Mihai Craiu
Journal:  Maedica (Bucur)       Date:  2021-09

Review 4.  Prevalence of developmental dyslexia in primary school children: a protocol for systematic review and meta-analysis.

Authors:  Li-Ping Yang; Chun-Bo Li; Xiu-Mei Li; Man-Man Zhai; Jing Zhao; Xu-Chu Weng
Journal:  World J Pediatr       Date:  2022-06-27       Impact factor: 2.764

Review 5.  Physical activity behaviours in adolescence: current evidence and opportunities for intervention.

Authors:  Esther M F van Sluijs; Ulf Ekelund; Inacio Crochemore-Silva; Regina Guthold; Amy Ha; David Lubans; Adewale L Oyeyemi; Ding Ding; Peter T Katzmarzyk
Journal:  Lancet       Date:  2021-07-21       Impact factor: 79.321

6.  Blood pressure response to noise in children and adolescents.

Authors:  Christina Antza; Stella Stabouli
Journal:  J Clin Hypertens (Greenwich)       Date:  2020-07-23       Impact factor: 3.738

7.  Serum Periostin as a Potential Biomarker in Pediatric Patients with Primary Hypertension.

Authors:  Michał Szyszka; Piotr Skrzypczyk; Anna Stelmaszczyk-Emmel; Małgorzata Pańczyk-Tomaszewska
Journal:  J Clin Med       Date:  2021-05-15       Impact factor: 4.241

8.  Neutrophil to Lymphocyte Ratio Is Increased and Associated With Left Ventricular Diastolic Function in Newly Diagnosed Essential Hypertension Children.

Authors:  Miao Hou; Lei Cao; Yueyue Ding; Ye Chen; Bo Wang; Jie Shen; Wanping Zhou; Jie Huang; Qiuqin Xu; Haitao Lv; Ling Sun
Journal:  Front Pediatr       Date:  2021-05-19       Impact factor: 3.418

9.  The associations between noise annoyance and psychological distress with blood pressure in children and adolescents: The CASPIAN-V Study.

Authors:  Negin Badihian; Roya Riahi; Mostafa Qorbani; Mohammad Esmaeil Motlagh; Ramin Heshmat; Roya Kelishadi
Journal:  J Clin Hypertens (Greenwich)       Date:  2020-08-02       Impact factor: 3.738

10.  Epidemiology of Obesity and Hypertension in School Adolescents Aged 15-17 from the Region of Central Poland-A Cross-Sectional Study.

Authors:  Piotr Wieniawski; Bożena Werner
Journal:  Int J Environ Res Public Health       Date:  2021-03-01       Impact factor: 3.390

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.